Tag: branded generics market insights

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What is the Projected CAGR for the Branded Generics Market Size from 2025 to 2034?#_x000D_

In the last few years, the market size of branded generics has significantly expanded. It’s anticipated to surge from $363.49 billion in 2024 up to $393.5 billion in 2025, marking a compound annual growth rate (CAGR) of 8.3%. Factors contributing to this growth during the historic period include cost-effectiveness and affordability, expiration of patents, market expansion and accessibility, government policies and initiatives, as well as healthcare reforms._x000D_

_x000D_

The market size for branded generics is projected to experience swift expansion in the coming years, ballooning to $588.37 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 10.6%. Factors influencing the growth during this forecast period include an increased need for generic biologics, the prevalence of chronic diseases, emerging markets development, and emphasis on biosimilars. Key trends for this period encompass strategic alliances and collaborations, technological progression, focus on long-term illness, market amalgamation, and patient-centered approach._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp_x000D_

_x000D_

#How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theBranded Generics Market?#_x000D_

The branded generics market is set to grow due to the rising occurrence of chronic illnesses. These are enduring diseases which while not completely curable, can be managed effectively. The rise in chronic diseases can be attributed to factors such as increasing consumption of tobacco, poor diet, lack of physical exercise, high alcohol intake and other similar factors. Globally, consumers are gravitating towards branded generics for managing chronic illnesses as these are more financially viable compared to regular medications. For example, in the 2022 Highlights released by the World Health Organisation (WHO), a health agency based in Switzerland, in September 2022, it was reported that out of all global deaths, 74% or 41 million deaths are due to noncommunicable diseases (NCDs) or chronic illnesses, annually. Hence, the growing incidence of chronic illnesses is predicted to propel the demand for branded generics over the projected period._x000D_

_x000D_

#Which Segments in the Branded Generics Offer the Most Growth?#_x000D_

The branded generics market covered in this report is segmented – _x000D_

_x000D_

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs_x000D_

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration_x000D_

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds _x000D_

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues _x000D_

3) By Hormones: Corticosteroids, Thyroid Hormones _x000D_

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers _x000D_

5) By Lipid Lowering Drugs: Statins, Fibrates _x000D_

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) _x000D_

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics _x000D_

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs _x000D_

9) By Other Drugs: Analgesics, Antibiotics, Antivirals _x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp_x000D_

_x000D_

#What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theBranded Generics Market?# Market?#_x000D_

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Current Market Growth and Trends in the Branded Generics Industry?#_x000D_

Collaborative undertakings are emerging as a primary trend in the branded generics sector. Firms within this market are forming alliances with suitable partners to capitalize on each other’s assets and extend their reach into fresh territories. For instance, in September 2024, Biocon Ltd., an Indian pharmaceutical entity, established a partnership with Tabuk Pharmaceuticals. Biocon’s role will be in the production and development of GLP-1 products, ensuring top-notch biopharmaceuticals specifically designed for diabetes management. Tabuk Pharmaceuticals, on the other hand, will possess marketing authorization rights and will supervise the registration, import, and promotion of these offerings throughout the Middle East, primarily in Saudi Arabia. This deal also accommodates provisions for potential expansion into other GLP products beyond the initial offerings, enabling a wider spectrum of diabetes therapies. The aim of this alliance is to create distinctive health solutions to uplift patients’ health quality in Saudi Arabia and nearby regions, in line with the commitment of both companies towards enhancing healthcare accessibility. Tabuk Pharmaceuticals, headquartered in Saudi Arabia, deals in the marketing of branded and generic pharmaceutical goods._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report_x000D_

_x000D_

#What Are the Key Elements That Define the Branded Generics Market?#_x000D_

Branded generics refer to an unregistered drug that is marketed under a brand name and provides patients and healthcare providers with a benefit that encourages them to choose the brand. These are the generic medications that have a unique brand name on the market. They might be advertised similarly to how branded medications are._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7186_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Branded Generics Market Size Changed, over the years?

The market size of branded generics has seen significant expansion in the last few years. The market’s value is expected to rise from $363.49 billion in 2024 to $397.19 billion in 2025, with a compound annual growth rate (CAGR) of 9.3%. Factors contributing to this growth during the historical period include cost efficiency and affordability, expiration of patents, market outreach and expansion, government strategies and policies, and healthcare reforms.

How Much Will the Branded Generics Market Be Worth in 2029?

The market for branded generics is anticipated to experience significant expansion in the upcoming years, reaching a size of $601.4 billion in 2029, with a compound annual growth rate (CAGR) of 10.9%. This growth in the projected timeline can be credited to the increasing demand for generic biologics, escalating incidences of chronic diseases, expansion of emerging markets, and the emphasis on biosimilars. The future trends to watch include strategic alliances and collaborations, technological evolution, focus on chronic ailments, market consolidation, and a patient-centric approach.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

Which is the Largest Company in the Branded Generics Market?

Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

What Are the Main Market Drivers in the Branded Generics Industry?

As chronic diseases become more prevalent, they will stimulate an increase in the growth rate of the branded generics market. The unhealable but treatable nature of chronic diseases is escalating due to factors such as increased usage of tobacco products, subpar nutrition habits, lack of physical activity, oversuse of alcohol, among other things. Globally, consumers prefer branded generics in the management of chronic diseases because they are more affordable than standard medications. For instance, the World Health Organization (WHO), a health organization based in Switzerland, highlighted in September 2022 that noncommunicable diseases (NCDs) or chronic diseases accounted for 41 million deaths, constituting 74% of global deaths annually. Consequently, with the escalating prevalence of chronic diseases, demand in the branded generics market is projected to surge during the forecast period.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

How Is the Branded Generics Market Segments Structured?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

What Strategic Trends Are Transforming the Branded Generics Market?

The trend of strategic alliances is shaping the branded generics market significantly. Firms engaged in branded generics are forging alliances with appropriate businesses in order to leverage mutual resources and penetrate new market domains. Biocon Ltd., an Indian pharmaceutical firm, reflected this in its alliance with Tabuk Pharmaceuticals in September 2024. With a focus on creating high-quality biopharmaceuticals customized for diabetes treatment, Biocon took responsibility for the development and production of GLP-1 products. At the same time, Tabuk Pharmaceuticals obtained the rights to market authorization and took up the job of registering, importing, and promoting these products, especially in the Middle Eastern region, primarily Saudi Arabia. Provisions for future extensions to other GLP products beyond the initial offerings were also included in the deal, offering a wider variety of diabetes care options. The aim of this partnership is to provide innovative health solutions that enhance patient welfare in Saudi Arabia and neighbouring regions, reflecting the commitment of both companies to elevate healthcare accessibility. Tabuk Pharmaceuticals, based in Saudi Arabia, brings to market both branded and generic pharmaceutical offerings.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Which Global Regions Offer the Highest Growth in the Branded Generics Market?

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7186

This Report Delivers Insight On:

1. How big is the branded generics market, and how is it changing globally?

2. Who are the major companies in the branded generics market, and how are they performing?

3. What are the key opportunities and risks in the branded generics market right now?

4. Which products or customer segments are growing the most in the branded generics market?

5. What factors are helping or slowing down the growth of the branded generics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the branded generics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Fast Is The Branded Generics Market Expected to Grow Between 2025 And 2029?

The size of the branded generics market has seen a robust expansion in the recent past. It is expected to escalate from $363.49 billion in 2024 to $397.19 billion in 2025, with a compound annual growth rate (CAGR) of 9.3%. The factors propelling the growth during the previous period include cost-effectiveness and affordability, expiration of patents, growth in market availability and access, government actions and directives, and healthcare restructuring.

The market size for branded generics is poised for swift expansion in the coming years, with projections for a rise to $601.4 billion in 2029, representing a compound annual growth rate (CAGR) of 10.9%. This growth in the projected period is due to a surge in the demand for generic biologics, an increase in chronic diseases, the expansion of emerging markets, and a concentration on biosimilars. Strategic partnerships and collaborations, advancements in technology, focus on chronic diseases, market consolidation, and a patient-centered approach are expected to be the principal trends during the forecast period.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theBranded Generics Market?

The escalation in the incidence of chronic illnesses is anticipated to propel the growth of the branded generics market. Chronic illnesses are enduring ailments that often remain unhealed; however, they are manageable and treatable. The upsurge in the occurrence of these diseases is attributable to factors such as increased consumption of tobacco products, undernutrition, physical inactivity, excessive alcohol use, and so forth. Globally, customers are favoring branded generics for the management of chronic conditions due to their lower cost compared to regular medications. For example, the World Health Organization’s 2022 Highlights reported in September 2022 that noncommunicable diseases (NCDs) or chronic diseases caused 41 million deaths, representing 74% of all global deaths annually. This intergovernmental health organization, based in Switzerland, notes the significant role of such diseases. Thus, the rising prevalence of chronic diseases is likely to stimulate more demand for branded generics throughout the predicted period.

Which Segments in the Branded Generics Offer the Most Growth?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theBranded Generics Market?# Market?

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Branded Generics Industry?

The trend of strategic alliance is pivotal in the branded generics market. Companies involved in branded generics are forming alliances with suitable businesses to maximize mutual resources and branch out into new market areas. For example, Biocon Ltd., a pharmaceutical firm based in India, entered into a partnership with Tabuk Pharmaceuticals in September 2024. Biocon has taken the responsibility of developing and producing GLP-1 products, ensuring top-quality biopharmaceuticals designed specifically for diabetes care. Meanwhile, Tabuk Pharmaceuticals has procured the rights to market authorization and will oversee the products’ registration, import, and promotion throughout the Middle East, especially in Saudi Arabia. The agreement also encompasses provisions for further expansion into other GLP products beyond the original offerings, enabling a wider spectrum of diabetes treatments. The alliance aims to provide unique health solutions that improve the health of patients in Saudi Arabia and adjacent regions, in line with both firms’ pledge to enhance access to healthcare. Tabuk Pharmaceuticals, based in Saudi Arabia, markets both branded and generic pharmaceutical products.

View the full report here:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

What Are the Key Elements That Define the Branded Generics Market?

Branded generics refer to an unregistered drug that is marketed under a brand name and provides patients and healthcare providers with a benefit that encourages them to choose the brand. These are the generic medications that have a unique brand name on the market. They might be advertised similarly to how branded medications are.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7186

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Primary Drivers Are Supporting the Continued Market Growth of theBranded Generics Market?

The rising trend of chronic diseases is seen as a catalyst for the growth of the branded generics market. Chronic illnesses, often incurable but manageable, are seeing a surge due to factors such as increased tobacco use, malnutrition, lack of physical activity, and overconsumption of alcohol, among others. Globally, consumers prefer branded generics for dealing with chronic ailments, given their cost-effectiveness compared to regular medications. As an example, the World Health Organization’s (WHO) 2022 Highlights in September 2022 listed that out of the 41 million deaths worldwide, 74% were a result of noncommunicable diseases (NCDs) or chronic illnesses. Thus, the surge in incidents of chronic diseases is likely to stimulate the demand for branded generics in the coming years.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

#What is the Anticipated CAGR of the Branded Generics Market, and What Factors Will Drive It?

In recent times, there has been a robust expansion in the size of the branded generics market. It is projected to rise from $363.49 billion in 2024 to $397.19 billion in 2025, registering a compound annual growth rate (CAGR) of 9.3%. Factors that have contributed to the growth during the historical period include affordability and cost savings, patent expiry dates, market proliferation and accessibility, governmental strategies and regulations, as well as healthcare overhauls.

Fast-paced expansion is projected for the branded generics market in the forthcoming years, with its size anticipated to reach $601.4 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.9%. Factors contributing to this growth during the forecast period include the escalating demand for generic biologics, the surge in chronic diseases, the expansion of emerging markets, and emphasis on biosimilars. Other key trends over the forecast period encompass strategic alliances and collaborations, advancements in technology, concentration on chronic diseases, market consolidation, and a patient-oriented approach.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7186

How Are Consumer Market Innovations Shaping the Current and Future Landscape of the Branded Generics Market?

Collaborative alliances are emerging as a significant trend in the branded generics marketplace. Companies within this sector are forming strategic collaborations with related businesses to effectively utilize each other’s resources and venture into unexplored markets. For instance, an illustrative example occurred in September 2024 when Biocon Ltd., a pharmaceutical company based in India, forged a partnership with Tabuk Pharmaceuticals. Biocon assumed the responsibility of the development and manufacture of GLP-1 products, focusing on creating superb quality biopharmaceuticals designed for diabetes care. Tabuk Pharmaceuticals acquired marketing authorization rights and assumed the responsibility for the registration, import, and promotion of the products throughout the Middle East, primarily in Saudi Arabia. The arrangement also considers potential expansion into other GLP products, widening the spectrum of diabetes care possibilities. This partnership aims to provide unique healthcare solutions for enhancing patient well-being in Saudi Arabia and nearby regions, in line with both companies’ devotion to boosting healthcare accessibility. Tabuk Pharmaceuticals, headquartered in Saudi Arabia, markets both branded and generic pharmaceutical products.

Who Are the Key Market Players Influencing the Growth of the Corn and Branded Generics Industry?

Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Which Key Market Segments Comprise the Branded Generics Market and Drive Its Revenue Growth?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

Which Regions Are Emerging as Leaders in the Branded Generics Market?

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Branded Generics Market 2025, By The Business Research Company:

Dairy Alternatives Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dairy-alternatives-global-market-report

Natural Food Colors And Flavors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/natural-food-colors-and-flavors-global-market-report

Functional Food Ingredients Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/functional-food-ingredients-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the branded generics market size evolved in recent years?

In the past few years, the market size for branded generics has seen significant growth. From a value of $363.49 billion in 2024, it is expected to increase to $397.19 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.3%. Factors such as affordability and cost savings, patent expirations, expansion and accessibility of the market, government policies and initiatives, and healthcare reforms have been instrumental in this historic growth.

What are the predictions for the branded generics market size in the coming years?

In the coming years, the specialty insurance market size is anticipated to undergo swift expansion. Projections show an increment to $164.25 billion by 2029, with a compound annual growth rate (CAGR) of 10.7%. Factors contributing to growth in the projected period include impending cyber threats, the effects of climate change, readiness for pandemics, advancement in technology, development in the healthcare industry, and a changing legal scenario. The predicted trends encompass tailor-made insurance solutions for the cannabis sector, thriving demand for space insurance in the aerospace industry, exclusive coverage for fine art pieces and collectibles, proliferation of insurance for renewable energy ventures, and a heightened emphasis on employee benefits liability coverage.

Get your branded generics market report here!

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

What key factors are fueling the growth of the branded generics market?

The escalating occurrence of long-lasting illnesses, often curable but usually not healable, commonly known as chronic diseases, is propelling the upward trajectory of the branded generics market. The surge in chronic diseases correlates significantly with poor nutrition, increased tobacco use, lack of physical activity, and overconsumption of alcohol among others. This surge has globally influenced consumer behavior, with individuals opting for branded generics as a more cost-effective solution for treating chronic conditions compared to conventional medicines. As laid out in the World Health Organization’s (WHO) 2022 Highlights in September 2022, a Switzerland-based intergovernmental health body reiterated that noncommunicable diseases (NCDs) or chronic diseases were responsible for 41 million deaths, constituting 74% of global mortality. Therefore, the swelling prevalence of chronic conditions is likely to stimulate further demand for branded generics in the coming period.

How is the global branded generics market divided into key segments?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

Who are the key firms paving the way for growth in the branded generics market?

Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Which trends are expected to transform the branded generics market?

Collaborative strategic alliances have emerged as a prominent trend in the branded generics sector. Firms in this industry are forging alliances with suitable partners to mutually benefit from shared resources and penetrate new markets. For example, in September 2024, Biocon Ltd., a pharmaceutical entity from India, formed a partnership with Tabuk Pharmaceuticals. Under this collaboration, Biocon is tasked with developing and manufacturing GLP-1 products, thereby ensuring the availability of high-quality biopharmaceuticals for diabetes treatment. Tabuk Pharmaceuticals retains the rights for marketing authorization and will oversee the registration, importation, and promotion of these products in the Middle East, especially Saudi Arabia. The terms of the agreement entail scope for future extension to other GLP products than those initially offered, thereby facilitating a wider spectrum of diabetes treatments. The goal of this partnership is to provide distinctive health solutions that improve patient welfare in Saudi Arabia and its peripheries, keeping with the commitment of both companies to enhance healthcare accessibility. Tabuk Pharmaceuticals is a pharmaceutical firm based in Saudi Arabia that trades in both branded and generic pharmaceutical products.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7186

What regions are contributing significantly to the growth of the branded generics market?

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Gastrointestinal Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Pharmacies and Drug Stores Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pharmacies-and-drug-stores-global-market-report

Vitamin and Minerals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/vitamin-and-mineral-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Are the Projected Expansion Rates of the Branded Generics Market for the Next Decade?

The size of the branded generics market has seen significant growth in the past few years. The market, which is expected to expand from $363.49 billion in 2024 to $397.19 billion in 2025, will experience a compound annual growth rate (CAGR) of 9.3%. The notable growth in the previous years can be linked to factors such as cost-efficiency, patent expiries, wider market access, government policies and initiatives, as well as healthcare reforms.

In the coming years, the branded generics market is anticipated to experience swift expansion, increasing to a projected size of $601.4 billion by 2029 with a compound annual growth rate (CAGR) of 10.9%. This projected growth could be due to factors such as an increased demand for generic biologics, a rise in chronic diseases, the growth of nascent markets, and an emphasis on biosimilars. During the forecast period, prominent trends expected to emerge include strategic alliances and cooperation, technological progress, a concentration on chronic diseases, market stabilization and consolidation, and a patient-focused strategy.

What External and Internal Drivers Are Contributing to the Growth of the branded generics Market’s Growth?

The growth trajectory of the branded generics market is expected to be propelled by the escalating incidence of chronic diseases. These diseases, which persist over time and often have no cure, can nonetheless be managed and treated. Their occurrence is rising due to factors like the increasing consumption of tobacco, poor dietary habits, physical inactivity, and excessive alcohol use, among others. Globally, customers are showing a growing preference for branded generics in managing chronic illnesses due to their lower cost compared to regular medications. For example, the World Health Organization (WHO) 2022 Highlights, a report by the Switzerland-based intergovernmental health body, cited in September 2022 that 41 million, or 74% of all deaths worldwide, were attributed to noncommunicable diseases (NCDs) or chronic diseases annually. Therefore, the surging prevalence of chronic diseases is envisaged to stimulate the demand for branded generics throughout the forecasted period.

Get Your Free Sample of the Global Branded Generics Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

Which Companies Are Redefining the Future of the Branded Generics Market?

Major companies operating in the branded generics market include:

• Pfizer Inc._x000D_

• F. Hoffmann-La Roche AG_x000D_

• Sanofi SA_x000D_

• AstraZeneca plc_x000D_

• GlaxoSmithKline plc_x000D_

What Trends Are Poised to Drive the Future Success of the Branded Generics Market?

The trend of strategic alliances is significant within the branded generics market. Companies functioning in this market are partnering with related businesses to capitalize on one another’s resources, thereby expanding their reach into fresh markets. To illustrate, Biocon Ltd., a pharmaceutical firm from India, entered into a collaboration with Tabuk Pharmaceuticals in September 2024. Biocon’s role will involve the production and development of GLP-1 products, ensuring premium biopharmaceuticals specific to the treatment of diabetes. Conversely, Tabuk Pharmaceuticals will possess the rights for marketing authorization, while also managing the registration, importing and promotion of these items primarily in Saudi Arabia, which is located in the Middle East. The deal is inclusive of potential growth prospects into additional GLP items beyond the preliminary offerings, making way for a more comprehensive selection of diabetes care treatments. The primary objective of the partnership is to provide distinctive health solutions augmenting the well-being of residents in Saudi Arabia and adjoining regions, in sync with the healthcare accessibility improvement goals of both entities. Tabuk Pharmaceuticals operates its business based out of Saudi Arabia and promotes its line of branded and generic pharmaceutical goods.

Get Instant Access to the Global Branded Generics Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Which Key Market Segments Comprise the Branded Generics Market and Drive Its Revenue Growth?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

What Are the Leading Regions in the Branded Generics Market Expansion?

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Can We Define the Branded Generics Market and Its Key Components?

Branded generics refer to an unregistered drug that is marketed under a brand name and provides patients and healthcare providers with a benefit that encourages them to choose the brand. These are the generic medications that have a unique brand name on the market. They might be advertised similarly to how branded medications are.

Browse Through More Similar Reports By The Business Research Company:

Gastrointestinal Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Pharmacies and Drug Stores Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pharmacies-and-drug-stores-global-market-report

Vitamin and Minerals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/vitamin-and-mineral-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: